Skip to main content

Table 2 Treatment characteristics from SPRINT-2 [17]

From: Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

A. Efficacy and Discontinuation Rates
  Non-Black Cohort Black Cohort
  PR48 BOC/RGT BOC/PR48 PR48 BOC/RGT BOC/PR48
  (N = 311) (N = 316) (N = 311) (N = 52) (N = 52) (N = 55)
Sustained virologic response,% (95% confidence interval) distribution 40.2 (34.7–45.9) 66.8 (61.3–71.9) 68.5 (63.0–73.6) 23.1 (12.5–45.9) 42.3 (28.7–56.8) 52.7 (38.8–66.3)
Beta (123.00, 183.02) Beta (212.7, 105.85) Beta (216.12, 99.43) Beta (123.00, 183.02) Beta (212.7, 105.85) Beta (216.12, 99.43)
Probability of discontinuation before Week 24 for reasons other than futility, n/m (%) 46/311 (14.8) 49/316 (15.5) 46/311 (14.8) 10/52 (19.2) 12/52 (23.5) 8/55 (14.5)
Probability of discontinuation after Week 24 for reasons other than futility, n/m (%) 25/173 (14.5) 20/225 (8.9) 42/232 (18.1) 6/17 (33.3) 3/27 (11.1) 8/33 (22.9)
Probability of failing futility rule at Week 24, n/m (%) 92/265 (34.7) 42/267 (15.7) 33/265 (12.5) 25/42 (59.5) 13/40 (32.5) 14/47 (29.8)
Probability of being assigned and completing 28 weeks of treatment, n (%) NA 147 (46.5) NA NA 15 (28.8) NA
B. Side Effects Combined Cohorts
  PR48 BOC/RGT BOC/PR48
  (N = 363) (N = 368) (N = 366)
Anemia, n (%) 107 (29.5) 182 (49.5) 180 (49.2)
Erythropoietin use, n (%) 87 (24.0) 159 (43.2) 159 (43.4)
Mean duration of anemia, Days 128.3 107.9 145.0
Mean duration of erythropoietin use, days 121.4 93.5 156.4
  1. PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.